In April 2017, Foresite Capital announced that Dr. Molly He had been hired as a venture partner. Dr. He previously served as Illumina’s senior director. Dr. He is recognized for her vast experience in genomic and pharmaceutical study and development. According to the CEO and MD of Foresite Capital Jim Tananbaum, Molly is a highly respected scientific researcher and was a great pleasure to join his team. Her expertise in the development of drugs and genomics, and also her excellent leadership skills means she is the perfect person to take Foresite to the next level.
While serving at Illumina, Molly He was responsible for the company’s innovations and improvements of its products, reveals Business Wire. Before she joined Illumina, Dr. He served at Pacific Biosciences where she was in charge of the development of protein reagent. Dr. Molly had spent 10 years in the pharmaceutical industry developing drugs for the treatment of cancer and immune ailments. She received her undergraduate degree in Biochemistry from Nankai University, and her doctorate degree in protein biophysics from Los Angeles based University of California. Molly has authored over 20 published materials and also the same number of patent applications.
About Jim Tananbaum
Jim Tananbaum is the founder and Chief Executive Officer of Foresite Capital. He is recognized for investing in companies operating in the healthcare industry. Before Jim created Foresite Capital, he had co-founded two biopharmaceutical firms and two healthcare investment providers. Jim began his career soon after completing his studies at Harvard Medical School, where he founded GelTex Pharmaceuticals. The firm was responsible for developing two drugs with less than $80 million. GelTex was later acquired for $1.6 billion, and the two drugs today generate annual revenues of $1 billion.
Theravance Inc. was another company founded by Jim. Together with its affiliate, Theravance Biopharm, Inc. they have a market cap of $2.75 billion. Jim has also played critical role in the investment industry by co-founding Prospect Venture Partners II and III as well as Sierra Ventures. He obtained his B.S. and B.S.E.E. from Yale, and his MD and M.B.A. from Harvard Medical School and Harvard Business School respectively.